Biolojic Design · raw details

Human Antibody Therapeutics · Rehovot · Founded 2010

active Seed ← back to profile

Highlights

1 patentProfile claimed by owner

About

Human Antibody Therapeutics

Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic Design has developed a new tool to re-engineer antibodies to bind new epitopes in a process known as re-epitoping. This technology has been shown to yield functional antibodies in difficult targets. Using proprietary algorithms, the company identifies an existing antibody that can be re-epitoped to bind the desired target. The antibody template is then engineered in an iterative computational and experimental approach to bind the desired epitope with high affinity. In 2014, Biolojic partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets selected by MedImmune, using Biolojic's computational and biochemical tools.

Identity

NameBiolojic Design
Slugbiolojic-design
Type / kindstartup
Crunchbase IDbiolojic-design
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6VxYsJDA

Status

Statusactive
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityRehovot
HQ addressHaMada St 12, Rehovot, Israel

Web & social

Websitehttps://biolojic.com
Careers pagehttps://www.biolojic.com/careers
LinkedInhttps://www.linkedin.com/company/18152425
Facebookhttps://www.facebook.com/BiolojicDesign

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDigital HealthcareMedical Decision Support
Technologies
BiologicalsMoleculesArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
bioconvergencetherapeuticsbioinformaticsdecision-supportnanotechnologyroboticsdigital-healthcaredrug-discoveryimmunologyhealthcarecancer-therapyantibodiesartificial-intelligencepharma-companies

Funding

Total raised$4.0M
Current stageSeed

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}